Antibiotics Need Additional Development Incentives, FDA Says
CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."
CDER Director Woodcock tells House panel that a guidance clarifying trial designs is not enough, an acknowledgement a Cubist executive calls a "break-through."